Concurrent preclinical studies confirmed the limited impact on 18F-FDG uptake in EGFR-altered GBM tumor, suggesting this limitation may be due to inability of the EGFR TKI to robustly inhibit extracellular domain mutant EGFR signaling in GBM. This evidence concerns the gene EGFR and glioblastoma.